Immune Checkpoint Inhibitors: all 7,569 studies that test it

Page 42 of 76. Open to participants first (2,567), then studies with results posted, then the rest; newest registration first within each.

• Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)CompletedNCT01943461Phase 1Results posted
• Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.CompletedNCT01928576Phase 2Results posted
• A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid TumorsCompletedNCT01928394Phase 1/2Results posted
• Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic MelanomaCompletedNCT01927419Phase 2Results posted
• Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid MalignanciesCompletedNCT01919619Phase 2Results posted
• Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)CompletedNCT01905657Phase 2/3Results posted
• A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"CompletedNCT01903993Phase 2Results posted
• FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic CancerCompletedNCT01896869Phase 2Results posted
• Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)CompletedNCT01876511Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)CompletedNCT01866319Phase 3Results posted
• HD IL-2 + Ipilimumab in Patients With Metastatic MelanomaTerminatedNCT01856023Phase 4Results posted
• Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)CompletedNCT01848834Phase 1Results posted
• A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]CompletedNCT01846416Phase 2Results posted
• Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)CompletedNCT01844505Phase 3Results posted
• Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant MesotheliomaActive, not recruitingNCT01843374Phase 2Results posted
• Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)CompletedNCT01840579Phase 1Results posted
• Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic MelanomaTerminatedNCT01838200Phase 1Results posted
• Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)CompletedNCT01820754Phase 2Results posted
• Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate CancerCompletedNCT01804465Phase 2Results posted
• Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)CompletedNCT01783938Phase 2Results posted
• Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)CompletedNCT01772004Phase 1Results posted
• Ipilimumab and Local Radiation for Selected Solid TumorsTerminatedNCT01769222Phase 1Results posted
• Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic MelanomaCompletedNCT01721772Phase 3Results posted
• Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic RegimensCompletedNCT01721759Phase 2Results posted
• A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)CompletedNCT01721746Phase 3Results posted
• A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid TumorsCompletedNCT01714739Phase 1/2Results posted
• Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced MelanomaTerminatedNCT01709162Phase 2Results posted
• Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT01708941Phase 2Results posted
• Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)CompletedNCT01704287Phase 2Results posted
• Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets PtsCompletedNCT01701674Not applicableResults posted
• Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant MelanomaTerminatedNCT01696045Phase 2Results posted
• Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical CancerCompletedNCT01693783Phase 2Results posted
• A Phase 1/2 Study to Evaluate MEDI4736CompletedNCT01693562Phase 1/2Results posted
• Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced MelanomaCompletedNCT01681212Phase 2Results posted
• Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLCCompletedNCT01673867Phase 3Results posted
• Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced MelanomaCompletedNCT01673854Phase 2Results posted
• Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)CompletedNCT01668784Phase 3Results posted
• An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerCompletedNCT01658878Phase 1/2Results posted
• Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)CompletedNCT01642004Phase 3Results posted
• PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced MelanomaCompletedNCT01621490Phase 1Results posted
• Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian CancerCompletedNCT01611558Phase 2Results posted
• An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple MyelomaCompletedNCT01592370Phase 1/2Results posted
• Doxycycline, Temozolomide and Ipilimumab in MelanomaTerminatedNCT01590082Phase 1/2Results posted
• An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line ChemotherapyCompletedNCT01585987Phase 2Results posted
• Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal MelanomaCompletedNCT01585194Phase 2Results posted
• First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial CarcinomaCompletedNCT01524991Phase 2Results posted
• Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg IpilimumabCompletedNCT01515189Phase 3Results posted
• Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate CancerCompletedNCT01498978Phase 2Results posted
• RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMACompletedNCT01497808Phase 1/2Results posted
• Yervoy With Sylatron Unresectable Stage 3 or 4 MelanomaCompletedNCT01496807Phase 1Results posted
• Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by SurgeryCompletedNCT01473940Phase 1Results posted
• Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung CancerTerminatedNCT01471197Phase 2Results posted
• Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)CompletedNCT01454102Phase 1Results posted
• Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy AloneCompletedNCT01450761Phase 3Results posted
• Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation TherapyCompletedNCT01449279Phase 2Results posted
• Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate CancerTerminatedNCT01420965Phase 2Results posted
• Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)TerminatedNCT01400451Phase 1Results posted
• Ipilimumab + Androgen Depravation Therapy in Prostate CancerTerminatedNCT01377389Phase 2Results posted
• Phase I Biomarker Study (BMS-936558)CompletedNCT01358721Phase 1Results posted
• BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)CompletedNCT01354431Phase 2Results posted
• Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The ExtremityCompletedNCT01323517Phase 2Results posted
• Gemcitabine and CT-011 for Resected Pancreatic CancerTerminatedNCT01313416Phase 2Results posted
• Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)CompletedNCT01295827Phase 1Results posted
• Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and CarboplatinCompletedNCT01285609Phase 3Results posted
• Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by SurgeryActive, not recruitingNCT01274338Phase 3Results posted
• Neoadjuvant Ipilimumab in Prostate CancerCompletedNCT01194271Phase 2Results posted
• Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung CancerCompletedNCT01165216Phase 1Results posted
• Ipilimumab + Temozolomide in Metastatic MelanomaCompletedNCT01119508Phase 2Results posted
• Phase 3 Study of Immunotherapy to Treat Advanced Prostate CancerCompletedNCT01057810Phase 3Results posted
• Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant MelanomaCompletedNCT01024231Phase 1Results posted
• Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced MelanomaCompletedNCT00920907Phase 1Results posted
• Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular LymphomaCompletedNCT00904722Phase 2Results posted
• Study of Immunotherapy to Treat Advanced Prostate CancerCompletedNCT00861614Phase 3Results posted
• ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in JapanCompletedNCT00836888Phase 1Results posted
• Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic CancerCompletedNCT00836407Phase 1Results posted
• Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, DacarbazineCompletedNCT00796991Phase 1Results posted
• A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent MalignanciesCompletedNCT00730639Phase 1Results posted
• CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate CancerTerminatedNCT00702923Phase 1Results posted
• Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III MelanomaCompletedNCT00636168Phase 3Results posted
• Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain MetastasesCompletedNCT00623766Phase 2Results posted
• Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV MelanomaCompletedNCT00610857Phase 2Results posted
• CT-011 MAb in DLBCL Patients Following ASCTCompletedNCT00532259Phase 2Results posted
• Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)CompletedNCT00527735Phase 2Results posted
• Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV MelanomaCompletedNCT00471887Phase 2Results posted
• A Study of MDX-1106 in Patients With Selected Refractory or Relapsed MalignanciesCompletedNCT00441337Phase 1Results posted
• A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.CompletedNCT00378482Phase 2Results posted
• Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV MelanomaCompletedNCT00324155Phase 3Results posted
• Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate CancerCompletedNCT00323882Phase 1/2Results posted
• Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate CancerCompletedNCT00170157Phase 2Results posted
• A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab StudiesCompletedNCT00162123Phase 2Results posted
• A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial SarcomaTerminatedNCT00140855Phase 2Results posted
• MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By SurgeryCompletedNCT00112580Phase 2Results posted
• MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic MelanomaCompletedNCT00094653Phase 3Results posted
• MDX-010 in Treating Patients With Recurrent or Refractory LymphomaTerminatedNCT00089076Phase 1/2Results posted
• Safety and Preliminary Antitumor Activity of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural MesotheliomaActive, not recruitingNCT07885306Phase 1
• Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell CarcinomaActive, not recruitingNCT07881900Phase 3
• Comparative Pharmacokinetics of SHR-8068 and Ipilimumab in Healthy Chinese MenCompletedNCT07852325Phase 1
• A Study of Tislelizumab Combined With TAC Regimen as Neoadjuvant Therapy for TNBCCompletedNCT07827079Phase 2
• Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal JunctionActive, not recruitingNCT07776639Phase 2
• Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract CancerActive, not recruitingNCT07635290Phase 2

← Immune Checkpoint Inhibitors overview